89Zr-ss-Pertuzumab

N/A

Report date: 2025/09/24 16:01:07

Base Information

Drug Name89Zr-ss-Pertuzumab
Drug Alias NameN/A
ClassificationRadiation-emitting products > Radioactive diagnostic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Zirconium > 89Zr +[4] 
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of HealthMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A